Group items tagged

High dosage of vitamin D3 is safe for obese adolescents, say University of Missouri researchers.

Examining the chin and upper and lower abdomen could be the most reliable and minimally invasive way to screen for excessive hair growth in women.

Light alcohol intake linked to increased risk of breast cancer, finds US study.

A new study has revealed that Britain spends over £34 billion a year on the care for patients suffering from Alzheimer's disease and dementia.

When people dream they are performing a particular action, a part of their brain involved in the planning and execution of movement lights up with activity, says a new study.

It may come as a shock to many readers about the extent of breach of patient records, as recently, personal details and a photograph of a patient have been posted on Facebook by the NHS.

PBR Staff Writer Published 27 March 2014 The European Commission (EC) has granted marketing authorization for GlaxoSmithKline's (GSK's) once-weekly diabetes treatment, Eperzan (albiglutide). The drug is indicated for the treatment of type 2 diabetes mellitus in adults, to improve glucose control as monotherapy, when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to contraindications or intolerance.

PBR Staff Writer Published 20 March 2014 Ireland-based specialty pharmaceutical firm Actavis has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to its generic version of Daytrana (Methylphenidate Transdermal System). Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.

PBR Staff Writer Published 25 March 2014 US-based Goodwin Biotechnology has entered into an agreement with Aspyrian Therapeutics for the technology transfer, process development, scale-up, and cGMP manufacturing of a new Antibody Drug Conjugate (ADC) for use in Phase I clinical trials.

PBR Staff Writer Published 21 March 2014 Novartis has launched the Lucentis (ranibizumab) pre-filled syringe (PFS) in Germany and plans to introduce the product in other markets throughout 2014. In October 2013, the company has received approval from the European authorities for Lucentis PFS, which is a new way of administering Lucentis that is specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.

Research and development (R&D) in liquid biopsy is increasingly being funded by both public and private sectors due to its promising features such as early detection of cancer tumour, new lesion characterisation and identification of cancer drug target.

India is witnessing a rise in confirmed Covid-19 cases. Credit: CDC on Unsplash Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates